As no previous studies had examined the effects of SGLT2 inhibitors on LVGLS at the time of trial design, we used data from studies assessing LV volume, a common marker for evaluating the impact of drug therapies on HF survival [17]. Here, SLC5A2 is linked to hydrops fetalis.